Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Severstal acquired A Group's sales network

4/4/24 CHMF

Board of Directors of KuibyshevAzot recommended that dividends be paid for 2023

4/4/24 KAZT

Tinkoff created its own NPF

4/4/24 T

Government and Novatek to invest ₽24.3 billion to build LNG equipment

4/4/24 NVTK

Delimobil reported 2023 by IFRS

4/4/24 DELI

Softline reported for 2023 by RAS

4/3/24 SOFL

Ingrad reported for 2023 by RAS

4/3/24 INGR

Sollers in Q1 increased sales by 30%

4/3/24 SVAV

UWC reported for 2023 by RAS

4/3/24 UWGN

Lukoil reduced production but maintained oil exports

4/3/24 LKOH